Experienced in Pemphigus Vulgaris

Yujun S. Dong

No. 8 Xishiku Street, 
Beijing, CN 
Experienced in Pemphigus Vulgaris
No. 8 Xishiku Street, 
Beijing, CN 
OverviewLocationsClinical Research

Overview

Yujun Dong practices in Beijing, China. Mr. Dong is rated as an Experienced expert by MediFind in the treatment of Pemphigus Vulgaris. His top areas of expertise are Light Chain Deposition Disease (LCDD), Lymphoid Hyperplasia, Cervical Polyps, Castleman Disease, and Bone Marrow Transplant.

His clinical research consists of co-authoring 55 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 4 articles in the study of Pemphigus Vulgaris.

Gender
Male

Locations

No. 8 Xishiku Street, Beijing, 100034, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
Enrollment Status: Active_not_recruiting
Publish Date: May 28, 2025
Intervention Type: Drug
Study Drugs: LOXO-305, Ibrutinib, Acalabrutinib, Zanubrutinib
Study Phase: Phase 3
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Pirtobrutinib, Idelalisib, Bendamustine, Rituximab
Study Phase: Phase 3
A National, Prospective, Non-interventional Study of NINLARO in Real World Clinical Practice
A National, Prospective, Non-interventional Study of NINLARO in Real World Clinical Practice
Enrollment Status: Active_not_recruiting
Publish Date: April 10, 2025
View 2 Less Clinical Trials

55 Total Publications

Multi-task learning with sleep features for interictal epileptiform discharge detection: a model development and validation study
Multi-task learning with sleep features for interictal epileptiform discharge detection: a model development and validation study
Journal: Zhonghua yi xue za zhi
Published: August 24, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Dong's expertise for a condition
ConditionClose
    View All 20 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile